Literature DB >> 34618580

Filling in the GAPs in understanding RAS.

Adrienne D Cox1,2,3, Channing J Der1,3.   

Abstract

A newly identified regulator increases the efficacy of a new class of targeted anti-RAS drugs.

Entities:  

Year:  2021        PMID： 34618580      PMCID： PMC8680106          DOI： 10.1126/science.abl3639

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  8 in total

1.  A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants.

Authors:  M Trahey; F McCormick
Journal:  Science       Date:  1987-10-23       Impact factor: 47.728

Review 2.  Drugging RAS: Know the enemy.

Authors:  Bjoern Papke; Channing J Der
Journal:  Science       Date:  2017-03-16       Impact factor: 47.728

Review 3.  Regulator of G-protein signaling (RGS) proteins as drug targets: Progress and future potentials.

Authors:  Joseph B O'Brien; Joshua C Wilkinson; David L Roman
Journal:  J Biol Chem       Date:  2019-10-21       Impact factor: 5.157

4.  The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS.

Authors:  Chuanchuan Li; Alberto Vides; Dongsung Kim; Jenny Y Xue; Yulei Zhao; Piro Lito
Journal:  Science       Date:  2021-10-07       Impact factor: 63.714

5.  Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism.

Authors:  Piro Lito; Martha Solomon; Lian-Sheng Li; Rasmus Hansen; Neal Rosen
Journal:  Science       Date:  2016-01-14       Impact factor: 47.728

6.  K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.

Authors:  Jonathan M Ostrem; Ulf Peters; Martin L Sos; James A Wells; Kevan M Shokat
Journal:  Nature       Date:  2013-11-20       Impact factor: 49.962

7.  Acquired Resistance to KRASG12C Inhibition in Cancer.

Authors:  Mark M Awad; Shengwu Liu; Igor I Rybkin; Kathryn C Arbour; Julien Dilly; Viola W Zhu; Melissa L Johnson; Rebecca S Heist; Tejas Patil; Gregory J Riely; Joseph O Jacobson; Xiaoping Yang; Nicole S Persky; David E Root; Kristen E Lowder; Hanrong Feng; Shannon S Zhang; Kevin M Haigis; Yin P Hung; Lynette M Sholl; Brian M Wolpin; Julie Wiese; Jason Christiansen; Jessica Lee; Alexa B Schrock; Lee P Lim; Kavita Garg; Mark Li; Lars D Engstrom; Laura Waters; J David Lawson; Peter Olson; Piro Lito; Sai-Hong I Ou; James G Christensen; Pasi A Jänne; Andrew J Aguirre
Journal:  N Engl J Med       Date:  2021-06-24       Impact factor: 91.245

8.  The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.

Authors:  Jill Hallin; Lars D Engstrom; Lauren Hargis; Andrew Calinisan; Ruth Aranda; David M Briere; Niranjan Sudhakar; Vickie Bowcut; Brian R Baer; Joshua A Ballard; Michael R Burkard; Jay B Fell; John P Fischer; Guy P Vigers; Yaohua Xue; Sole Gatto; Julio Fernandez-Banet; Adam Pavlicek; Karen Velastagui; Richard C Chao; Jeremy Barton; Mariaelena Pierobon; Elisa Baldelli; Emanuel F Patricoin; Douglas P Cassidy; Matthew A Marx; Igor I Rybkin; Melissa L Johnson; Sai-Hong Ignatius Ou; Piro Lito; Kyriakos P Papadopoulos; Pasi A Jänne; Peter Olson; James G Christensen
Journal:  Cancer Discov       Date:  2019-10-28       Impact factor: 38.272
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.